Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity

Cancer Research

Volumn 74, Issue 10, 2014, Pages 2710-2718

  Cecil, Denise L ^a   Holt, Gregory E ^b   Park, Kyong Hwa ^c   Gad, Ekram ^a   Rastetter, Lauren ^a   Childs, Jennifer ^a   Higgins, Doreen ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYSTEINE RICH PROTEIN 61; ENTACTIN; GAMMA INTERFERON; INTERLEUKIN 10; SOMATOMEDIN BINDING PROTEIN 2; THYROGLOBULIN; TRANSFORMING GROWTH FACTOR BETA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; TUMOR IMMUNOLOGY; TUMOR VOLUME;

ANIMALS; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTERFERON-GAMMA; INTERLEUKIN-10; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; T-LYMPHOCYTES, HELPER-INDUCER; TH2 CELLS;

EID: 84901263463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3286     Document Type: Article

References (37)

1. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010;16:5539-47.
2. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372:145-54.
3. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, nodenegative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66.
4. Ebert LM, Macraild SE, Zanker D, Davis ID, Cebon J, Chen W. ACancer Vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PloS One 2012;7:e48424.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-64.
6. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
7. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Engl J Med 2009;361: 1838-47.
8. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012; 39:296-304.
9. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27:4685-92.
10. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010;22:333-40.
11. Perret R, Sierro S, Botelho NK, Corgnac S, Donda A, Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013;73:6597-608.
12. Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol 2010;32:183-96.
13. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can controlCD4 T lymphocyte differentiation in vivo. J Expl Med 1995;181:1569-74.
14. Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing antitumour functions in CD40-Activated human macrophages in vitro. Eur J Immunol 2014;44:162-72.
15. Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous Tcell lymphoma. Clin Cancer Res 2013;19:3755-63.
16. Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008;68:8400-09.
17. Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, Kuus-Reichel K, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods. 2006;308:13-18.
18. Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, et al. Thelper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. Breast Cancer Res Treat 2013;139:657-65.
19. Harper B, McClain S, Ganko EW. Interpreting the biological relevance of bioinformatic analyses with T-DNA sequence for protein allergenicity. Regul Toxicol Pharmacol 2012;63:426-32.
20. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146-51.
21. Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, et al. A multi-Antigen vaccine targeting neu, IGFBP-2 and IGF-IR prevents tumor progression in mice with pre-invasive breast disease. Cancer Prev Res 2013;6:1273-82.
22. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4 T cells that facilitate tumor development. J Exp Med 2007;204:1037-47.
23. Pedroza-Gonzalez A, Xu K, WuTC, Aspord C, Tindle S,Marches F, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011;208:479-90.
24. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumorbearing mice. J Immunol. 1996;156:73-78.
25. Salazar-Onfray F, LopezMN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007;18:171-82.
26. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007;104: 20884-89.
27. Camacho SA, Carbobe FR, Sarvetnick N, LeBon A, Karlsson L, Peterson PA, et al. A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat Immunol 2001;2:523-29.
28. Li J, Sun Y, Jia T, Zhang R, Zhang K, Wang L. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int J Cancer 2014;134:1683-94.
29. Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1,2,3 and 4. Curr Opin Investig Drugs 2009;10:526-35.
30. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608.
31. Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, et al. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology 2013;2:e24962.
32. Mandapathil M, Visus C, Finn OJ, Lang S, Whiteside TL. Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology 2013;2:e25514.
33. Herman RA, Song P, Thirumalaiswamysekhar A. Value of eight-Aminoacid matches in predicting the allergenicity status of proteins: an empirical bioinformatic investigation. Clin Mol Allergy 2009;7:9.
34. Hansmann L, Schmidl C, Kett J, Steger L, Andreesen R, Hoffmann P, et al. Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol 2012;188:1275-82.
35. Caserta S,Kleczkowska J,Mondino A,ZamoyskaR. Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-Associated antigens. J Immunol 2010;185:6545-54.
36. Brentville VA, Metheringham RL, Gunn B, Durrant LG. High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One 2012;7:e41112.
37. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, et al. High-Avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2013;73:595-604.